Suppr超能文献

糖尿病中的毛细血管滤过与淋巴吸收。达弗隆500毫克的药效学活性应用。

Capillary filtration and lymphatic resorption in diabetes. Application to the pharmacodynamic activity of Daflon 500 mg.

作者信息

Behar A, Valensi P, de Champvallins M, Cohen-Boulakia F, Albagli B

机构信息

Hôpital Broussais, Paris, France.

出版信息

Int Angiol. 1989 Oct-Dec;8(4 Suppl):27-9.

PMID:2632646
Abstract

Microcirculatory disorders are often a complication of diabetes. They are associated with an increased capillary permeability which can be assessed by the Landis test using 99mTc-labelled albumin. Labelled albumin retention is measured by external detection (residual radioactivity after removal of venous tourniquet). The Fast Fourier Transform of the radioactivity disappearance graph reflects the lymphatic albumin resorption. Thirteen out-patients with diabetes from 1 to 19 years suffering from evident microcirculatory disorders were treated with a micronized flavonoid fraction: Daflon 500 mg (2 tablets per day) during a month. Antihypertensive and/or antidiabetic treatment were continued during the study if they were given before starting. A test was performed before, and at the end of the treatment. In 10 of the 13 patients, the test was carried out a third time 5.5 +/- 1.0 months later, after treatment withdrawal. Results were as follows: 1) labelled albumin retention was abnormal (greater than or equal to 8%) at the start and became normal in the patients and improved in 1 patient. After treatment withdrawal, the results of the third test were again abnormal, in the patients who had been normalized beforehand; 2) the initially abnormal lymphatic resorption became normal in six of the 13 patients at the end of the treatment and became abnormal again in all patients after treatment withdrawal. In a parallel group of 15 patients with abnormal test lymphatic fluctuations and not being treated with a vasculo-protector agent, the initially abnormal test remained abnormal 5 to 48 months later in all patients.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

微循环障碍通常是糖尿病的一种并发症。它们与毛细血管通透性增加有关,这可以通过使用99mTc标记白蛋白的兰迪斯试验来评估。标记白蛋白的滞留通过外部检测(去除静脉止血带后的残留放射性)来测量。放射性消失图的快速傅里叶变换反映了淋巴白蛋白的吸收情况。13名年龄在1至19岁、患有明显微循环障碍的糖尿病门诊患者接受了微粉化黄酮类成分治疗:达弗隆500毫克(每天2片),持续一个月。如果在研究开始前已进行抗高血压和/或抗糖尿病治疗,则在研究期间继续进行。在治疗前和治疗结束时进行了一项测试。13名患者中的10名在停药5.5±1.0个月后进行了第三次测试。结果如下:1)开始时标记白蛋白滞留异常(大于或等于8%),患者中该指标变为正常,1名患者有所改善。停药后,预先恢复正常的患者第三次测试结果再次异常;2)最初异常的淋巴吸收在13名患者中的6名患者治疗结束时恢复正常,停药后所有患者再次变为异常。在另一组15名测试淋巴波动异常且未接受血管保护剂治疗的患者中,最初异常的测试在所有患者中5至48个月后仍保持异常。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验